Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of patients with cancer in clinical trials has not been established. We conducted a phase 2 trial to evaluate the efficacy of pertuzumab plus trastuzumab for metastatic colorectal cancer (mCRC), with human epidermal g...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yoshiaki, Okamoto, Wataru, Kato, Takeshi, Esaki, Taito, Kato, Ken, Komatsu, Yoshito, Yuki, Satoshi, Masuishi, Toshiki, Nishina, Tomohiro, Ebi, Hiromichi, Sawada, Kentaro, Taniguchi, Hiroya, Fuse, Nozomu, Nomura, Shogo, Fukui, Makoto, Matsuda, Seiko, Sakamoto, Yasutoshi, Uchigata, Hiroshi, Kitajima, Kana, Kuramoto, Naomi, Asakawa, Takashi, Olsen, Steve, Odegaard, Justin I., Sato, Akihiro, Fujii, Satoshi, Ohtsu, Atsushi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604726/
https://www.ncbi.nlm.nih.gov/pubmed/34764486
http://dx.doi.org/10.1038/s41591-021-01553-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604726/
https://www.ncbi.nlm.nih.gov/pubmed/34764486
http://dx.doi.org/10.1038/s41591-021-01553-w

Ejemplares similares